Showing 7361-7370 of 8832 results for "".
- Skin Bleaching for a Lighter Complexion Carries Serious Riskshttps://practicaldermatology.com/news/skin-bleaching-for-a-lighter-complexion-carries-serious-risks/2460769/Despite the potential dangers of skin bleaching products, the global market for skin lighteners last year was estimated at $8.6 billion and is projected to reach $12.3 billion by 2027. “The cultural beliefs that promote the practice of skin bleaching date back centuries
- Biosimilar News: Switching Study Shows Cyltezo and Humira Are Interchangeablehttps://practicaldermatology.com/news/biosimilar-news-switching-study-shows-cyltezo-and-humira-are-interchangeable/2460762/Switching between adalimumab biosimilar Cyltezo and its reference product results in similar pharmacokinetics, efficacy, safety and immunogenicity in people with moderate-to-severe chronic plaque psoriasis, according to new Phase 3 data presented at the American Academy of Dermatology 2021 virtua
- Zoom Dysmorphia Fuels Boost in Cosmetic Consultshttps://practicaldermatology.com/news/zoom-dysmorphia-fuels-boost-in-cosmetic-consults/2460760/During the pandemic, there was a shift to remote work, and demand for video conferencing increased which sired a corresponding rise in the number of patients with negative self-perceptions seeking cosmetic consultations, a new survey shows. In a survey of more than 100 board-certified d
- Research Reveals How Skin May Repair Itselfhttps://practicaldermatology.com/news/research-reveals-how-skin-may-repair-itself/2460755/Activation of two transcription factors may enhance a natural process of skin cell division, a desirable outcome in regenerative medicine, according to a study in Nucleic Acid Research. In normal conditions, one in every four cells isolated from the inner layer of the skin
- And The Winners Are...BTL's Emsculpt Classic, Emsculpt NEO, and Emsella.https://practicaldermatology.com/news/and-the-winners-arebtls-emsculpt-classic-emsculpt-neo-and-emsella/2460751/BTL Aesthetics’ took home five awards from several aesthetic publications for Emsculpt Classic, Emsculpt NEO, and Emsella. Emsculpt therapy was named the winner of the 2020 Aestheticians Choice Award for Favorite Body Sculpting Device in Dermascop
- ASDSA Alerts Nation’s Governors to New Trend in Anti-transgender Legislationhttps://practicaldermatology.com/news/asdsa-alerts-nations-governors-to-new-trend-in-anti-transgender-legislation/2460749/The American Society for Dermatologic Surgery Association (ASDSA) sent a letter to all 50 state governors along with legislative leaders, alerting them to the increase in anti-transgender legislation that is proliferating in state legislatures across the country. After Arkansas be
- Yale Cancer Center Study Highlights Novel Immunotherapy Approach to Fight Melanomahttps://practicaldermatology.com/news/yale-cancer-center-study-shows-novel-immunotherapy-approach-to-fight-melanoma/2460748/A tumor-targeting and cell-penetrating antibody can stimulate an immune response to help treat melanoma, Yale researchers reported at the American Association of Cancer Research (AACR) virtual annual meeting. “Most approaches rely on direct injection into tumors of ribonucleic aci
- Industry Optimism Surges: Three Ways for Dermatologists to Capitalizehttps://practicaldermatology.com/news/industry-optimism-surges-three-way-for-dermatologists-to-capitalize/2460745/Despite a tumultuous past year, a recent Medscape survey shows that 85 percent of dermatologists are happy with their profession and optimistic about the future. This optimism is likely brought on by
- Thiazide Diuretics Linked to Skin Cancer Riskhttps://practicaldermatology.com/news/thiazide-diuretics-linked-to-skin-cancer-risk/2460744/Use of certain blood pressure-lowering medications may increase risk for skin cancer, a new study shows. Researchers reviewed data for nearly 303,000 adults in Ontario over age 65 who were prescribed medications for high bl
- Journey Medical to Acquire Dermira's Qbrexzahttps://practicaldermatology.com/news/journey-medical-to-acquire-dermiras-qbrexza/2460731/Journey Medical Corporation, a partner company of Fortress Biotech, Inc., has entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the US from Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company. The transaction is expected to close early in the secon